Featured Story

  • FDA puts clinical hold on Advaxis' cervical cancer vaccine

    On Sept. 18, Advaxis reported "encouraging" data from a Phase II trial of its cervical cancer vaccine, axalimogene filolisbac, dubbed ADXS-HPV. Now, the biotech is reporting an FDA clinical hold on the candidate--5 days after the FDA placed the hold.

Pfizer touts Trumenba immunogenicity when administered with Menactra, Adacel

In a potential boost to uptake and adherence, Pfizer reported promising data this week on its meningitis B vaccine Trumenba administered concomitantly with Menactra and Adacel from Sanofi Pasteur.

J&J brings Ebola vaccine to trial in Sierra Leone

Just three weeks after it struck up a $28.5 million government partnership to advance its Ebola vaccine, Johnson & Johnson announced on Friday that it is starting a safety and immunogenicity trial in Sierra Leone for its Ebola candidate.

Cipla, Serum partner to provide vaccines in S. Africa

Building on an existing relationship, Indian generics giant Cipla and vaccines outfit Serum Institute of India on Thursday announced a collaboration to bring Serum's vaccines to South Africa.

Pfizer completes acquisition of two GSK meningitis vaccines

In a move to ease antitrust concerns ahead of its multibillion-dollar asset swap with Novartis, GlaxoSmithKline announced in June that it would sell two of its mature meningitis jabs to Pfizer.

Allegheny General Hospital joins Sanofi's Cdiffense PhIII trial

The race to a Clostridium difficile vaccine has been dominated by Big Pharmas Sanofi and Pfizer, whose candidates were fast-tracked by the FDA in 2010 and 2014, respectively. Allegheny General Hospital in Pittsburgh announced on Wednesday that it will participate in Phase III trials for Sanofi's investigational vaccine.


From Our Sister Sites


Moderna Therapeutics' top scientist has quietly left the much-discussed company after two years at the helm of its R&D operation, walking away from a cash-flush biotech with big ambitions.


A new company spun out of Harvard University's Wyss Institute raised $5.15 million in Series A cash to develop a technology its founders say can generate images of unprecedented resolution, creating a new avenue for diagnostics and drug discovery.